Ervous system tumor microenvironment. Clin Cancer Res 2005, 11:5515-5525.6.7. 8.9.10.11.12.13.14.15.16.17.18. 19.20.21.22.23.Zeng G, Li
Ervous system tumor microenvironment. Clin Cancer Res 2005, 11:5515-5525.6.7. 8.9.10.11.12.13.14.15.16.17.18. 19.20.21.22.23.Zeng G, Li Y, El-Gamil M, Sidney J, Sette A, Wang RF, Rosenberg SA, Robbins PF: Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 2002, 62:3630-3635. van den Broek M, von Boehmer L, Knuth A: Developments in cancer immunotherapy. Dig Dis 2010, 28:51-56. Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, Miyamoto M, Morikawa T, Kondo S, Ikeda H, Nishimura T: Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 2006, 28:1089-1098. Tajima K, Obata Y, Tamaki H, Yoshida M, Chen YT, Scanlan MJ, Old LJ, Kuwano H, Takahashi T, Takahashi T, Mitsudomi T: Expression of cancer/ testis (CT) antigens in lung cancer. Lung Cancer 2003, 42:23-33. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ: Immunohistochemical analysis of NY-ESO1 antigen expression in normal and malignant human tissues. Int J Cancer 2001, 92:856-860. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, et al: Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody Mangafodipir (trisodium) cost responses in peptidevaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000, 97:12198-12203. Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y, Rao J, Li W, Chen D, Langford MP, et al: Dendritic cell surface calreticulin is a receptor for NYESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol 2006, 177:3582-3589. Sahin U, Koslowski M, Tureci O, Eberle T, Zwick C, Romeike B, Moringlane JR, Schwechheimer K, Feiden W, Pfreundschuh M: Expression of cancer testis genes in human brain PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28878015 tumors. Clin Cancer Res 2000, 6:3916-3922. Scanlan MJ, Gordon CM, Williamson B, Lee SY, Chen YT, Stockert E, Jungbluth A, Ritter G, Jager D, Jager E, et al: Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer 2002, 98:485-492. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, et al: Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. J Clin Oncol 2011. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997, 94:1914-1918. Jaenisch R, Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003, 33(Suppl):245-254. de Vos D, van Overveld W: Decitabine: a historical review of the development of an epigenetic drug. Ann Hematol 2005, 84(Suppl 1):3-8. Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, Maraskovsky E, Jager E, Seliger B, Maio M: 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 2002, 8:2690-2695. Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Sotomayor EM, PinillaIbarz JA: Treatment of chronic lymphocytic leukemia with a.
